Leveraging Precision Medicine to Improve the Lives of People with Diabetes
The American Diabetes Association is soliciting research proposals that leverage precision medicine-based approaches at all stages in the course type 1 diabetes and type 2 diabetes. While this call is broad in scope and encompasses basic through clinical research, significant emphasis will be placed on clinical research and translation. Applicants should explain how their proposal directly aligns with precision diagnostics, therapeutics, treatment, prognostics or monitoring, as outlined in the Precision Medicine Diabetes Initiative's first consensus report in 2020(link is external), (Diabetes Care® 2020 Jul;43(7):1617-1635). Importantly, submissions should indicate how the proposed research will have a significant impact (“move the needle”) on outcomes in those individuals living with diabetes.
Innovative Transformational Research to Reduce Health Disparities and Advance Health Equity in Diabetes
The American Diabetes Association is soliciting research to provide critical funding toward transformational and translatable research to enhance minority health and reduce health disparities to improve the lives of people living with diabetes and its complications. For this funding opportunity, attention must focus on, and all hypotheses should reflect, the impact of race/ethnicity, socioeconomic status, health care access, and/or other direct factors that underlie diabetes health disparities, and describe how results will transform assessment and treatment of underserved groups and address significantly improved outcomes in diabetes or its complications. We encourage formative research, intervention development, and/or pilot-testing of interventions.
For the purposes of this RFA, we encourage interventions that include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent and/or improve clinical outcomes for persons living with diabetes or it’s complications.
Leveraging Innovative Behavioral and Psychosocial Interventions for Diabetes Prevention through Nutrition & Lifestyle
ADA is soliciting research to elicit sustained behavioral change at the individual and community level with interventions tailored to different racial and socioeconomic groups across the life span. Importantly, applicants should indicate how the proposed research will have a significant impact (“move the needle”) on outcomes in those individuals at risk of, or living with, diabetes. The goal of this RFA is to identify person centered, yet scalable, dietary and lifestyle interventions with the greatest potential for adoption and maintenance of diabetes-preventing or diabetes-mitigating lifestyles by individuals at greatest risks.
Pathway to Stop Diabetes
Pathway to Stop Diabetes has a simple, yet revolutionary goal: to find scientists at the peak of their creativity and provide them with the flexibility and resources they need on the road to breakthrough discoveries. We attract and retain brilliant scientists in diabetes. Our three areas of focus—awarding research grants, providing access to scientific and career mentoring from leading diabetes researchers, and creating a diabetes think tank—are each key components of a unique formula to cultivate the next generation of leaders, whose discoveries will stop diabetes and all of its burdens once and for all.
Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) - Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This FOA invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D) and impaired awareness of hypoglycemia (IAH). A separate FOA (RFA-DK-21-020) invites Clinical Centers to: 1) determine if the most up-to-date diabetes technology to optimize HbA1c while minimizing hypoglycemia can restore awareness of hypoglycemia and improve counter-regulatory responses in individuals with T1D and IAH; 2) identify the magnitude and duration of time in range (TIR), time spent in hypoglycemia or other CGM metrics that are associated with restoration of awareness of hypoglycemia; and 3) determine the association of current or newly developed self-reported measures of IAH with counter-regulatory responses to elucidate the heterogeneity in restoration of hypoglycemia awareness.
Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)
The purpose of this FOA is to establish a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D). Individuals with IAH are often excluded from clinical trials and this omission contributes greatly to a lack of knowledge regarding the clinical characteristics which determine or predict an individual’s ability to restore hypoglycemic awareness. New technologies such as continuous glucose monitors (CGM) and closed loop systems (i.e. artificial pancreas) have been shown to reduce hypoglycemic events. However, despite a reduction in hypoglycemic events, restoration of hypoglycemia awareness does not occur in all individuals and the effects on improving the counter-regulatory responses are not known.
Cardiovascular Biorepository for Type 1 Diabetes (U24 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites a single cooperative agreement application for a data coordinating center that first establishes a biorepository of human cardiovascular (CV) tissue and then serves as a coordinating center resource for discovery and mechanistic research to increase our knowledge of the CV complications of type 1 diabetes (T1D).
Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed)
This initiative will support the development of tools and experimental platforms for the purification and characterization of Extracellular Vesicles (EV) originating from the human pancreatic islet and its broader tissue environment in healthy individuals, and individuals with T1D or at-risk of developing the disease.
Continuation of The Collaborative Islet Transplantation Registry (U01 Clinical Trial Not Allowed)
This FOA invites applications for continuation of the Collaborative Islet Transplantation Registry (CITR).
Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes – Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to better understand youth-onset type 2 diabetes.